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Following acute myocardial infarction, the human heart 
can lose over a billion cardiac myocytes. Th  e injured 
tissue undergoes ﬁ  brosis, leading to signiﬁ  cant loss of 
contractile function, adverse left ventricular remodeling 
and ultimately chronic heart failure. Adult mammalian 
cardiac myocytes are multinucleated and it has been well 
documented that only a limited number of cardiac 
myocytes enter the cell cycle following myocardial repair 
[1]. Scientists at the bench have known for decades that 
cardiac myocytes isolated from adult mammalian myo-
cardium do not enter the cell cycle and actively divide, 
whereas cardiac myocytes from neonatal myocardium do 
have a limited capacity to divide in culture. Th  e  limited 
proliferative capacity of adult cardiac myocytes correlates 
with the limited capacity of the adult myocardium to 
regenerate itself following acute myocardial infarction, 
and is in distinct contrast to the regenerative capacity of 
the myocardium in lower life forms, including zebraﬁ  sh 
[2].
Th  e recent publication by Porrello and colleagues 
sought to answer the question of whether the neonatal 
mammalian heart has the capacity for regeneration that 
is lost with aging [3]. To answer this question they 
resected the apex of the hearts of 1-day-old neonatal 
mice and found that the myocardium does regenerate. 
Th   e regenerative process is accompanied by proliferation 
of cardiac myocytes that peaked at 7 days after resection. 
By 21 days after resection the apex of experimental 
animals was indistinguishable from that of sham animals, 
without any evidence of signiﬁ   cant scar. Furthermore, 
cardiac function and chamber dimensions were similarly 
un  changed between experimental and sham-treated 
animals. In distinct contrast, apical resection in 7-day-old 
mice did not lead to cardiac myocyte proliferation or 
regenera  tion of the lost apical tissue. Rather, the apex in 
the 7-day-old mice was markedly ﬁ  brotic, suggesting that 
the regenerative capacity of neonatal myocardium is lost 
within the ﬁ  rst week of life.
Th  e ultimate issue is identifying the mechanism(s) 
behind myocardial regeneration in 1-day-old mice that is 
lost with aging, and whether this mechanism(s) can be 
re-established to achieve clinically meaningful regenera-
tion in patients with left ventricular dysfunction. Figure 1 
schematizes multiple potential mechanisms associated 
with myo  cardial repair that could be, and arguably need 
to be, investigated.
Since the seminal work of Orlic and colleagues [4,5], 
the ﬁ  eld of cardiac regeneration has demonstrated the 
potential to induce cardiac repair using adult stem cells; 
however, it is unlikely that a signiﬁ  cant mechanism of the 
observed beneﬁ  t is associated with myocardial regenera-
tion. Multiple stem cell populations have been studied 
and have demonstrated beneﬁ  t with multiple adult stem 
cell populations in preclinical studies [6,7] and in clinical 
populations [8-12]. Furthermore, the elucidation of rele-
vant mechanisms associated with myocardial repair [13,14] 
has led to novel clinical trials that focus on inducing 
endogenous repair in the absence of stem cell delivery 
(Clinicaltrials.gov: CXCL12, NCT01082094, Th  ymosinβ4 
and NCT01311518).
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and future strategies to prevent and treat cardiac 
dysfunction in clinical populations.
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attempted to determine whether the cardiac myocytes in 
the regenerated apical tissue were derived from endoge-
nous cardiac myocytes or a source of progenitor cells [3]. 
To address this question they cross the αMHC-
MerCreMer mouse with the Rosa26-lacZ reporter 
mouse. Th  e mice were treated with a single dose of 
tamoxifen at birth. Th  e dosing of tamoxifen led to 
chimeric cardiac myocytes with a speciﬁ  c  percentage 
being lacZ-positive. If the apex was regenerated from 
endogenous cardiac myocytes, then the regenerated 
tissue should have the same percen  tage of lacZ-positive 
cardiac myocytes; whereas if the tissue was regenerated 
from a progenitor pool, then the apex would have a 
higher percentage of lacZ-negative cardiac myocytes 
since the tamoxifen would not have activated the αMHC-
MerCreMer promoter in these cells. Th  e data nicely 
demonstrate that the regenerated apex had the same 
proportion of lacZ-positive cardiac myocytes as the 
endo  ge  nous myocardium [3], suggesting that the 
regenerated tissue was derived from endogenous cardiac 
myocytes. While this may be accurate, what is not taken 
into account is that the αMHC-MerCreMer promoter is 
activated in cardiac stem cells. Th  ese mice therefore 
probably have a chimera of lacZ-positive and lacZ-
negative cardiac stem cells from which the cardiac myo-
cytes in the regenerated apex could have been derived. 
Regardless, the ﬁ  ndings of the paper are relevant since 
there is little evidence that adult cardiac stem cells can 
regenerate cardiac myocytes [15].
Consistent with the observations by Porrello and 
colleagues with respect to myocardial regeneration, stem 
cell function and endogenous myocardial repair are lost 
with aging. We recently demonstrated that cardiac 
myocyte hypertrophy in response to pressure overload is 
age dependent. We further demonstrated that aging leads 
to a decline in the generation of bone-marrow-derived 
cardiac stem cells, and that the eﬀ  ects of aging on cardiac 
myocyte hypertrophy could be reversed by trans  plan-
tation of young bone marrow into aged mice [16].
Th  e loss of cardiac myocyte regeneration and repair 
with aging may help explain the rarity of cardiac tumors. 
Such observations suggest that dissecting the cardiac 
regenerative and reparative mechanisms lost with aging 
that have relevance to tumor suppression could yield 
important targets for future therapeutic approaches. One 
such example is our recent ﬁ  nding that downregulation 
of the tumor suppressor protein disabled-2 results in 
signi ﬁ   cantly improved stem-cell-based cardiac repair 
[17].
In summary, the study by Porrello and colleagues 
demonstrates that the complete regeneration of myo-
cardial tissue is possible in mammals [3]. Th  is  observation 
is important because we now know that myocardial 
Figure 1. Potential mechanisms for myocardial regeneration. Schematic of potential mechanisms for myocardial regeneration including 
chemokine/growth factor release, endogenous cardiac myocyte proliferation, proliferation and recruitment of endogenous cardiac stem cells and 
recruitment of bone-marrow-derived stem cells.
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can deﬁ   ne the associated mechanisms, and determine 
how these mechanisms are modulated by aging, new 
therapeutic strategies targeted at myocardial regeneration 
should be possible.
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